Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end
Ardelyx, Inc. · PHARMACEUTICAL PREPARATIONS · Now $5.73
+6.1% in 1d after detection
Post-detection moves
1h
—
1d
+6.1%
3d
+3.2%
7d
-3.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS